| Literature DB >> 25375146 |
Silvia Moretti1, Silvia Bozza1, Vasilis Oikonomou1, Giorgia Renga1, Andrea Casagrande2, Rossana G Iannitti1, Matteo Puccetti1, Cecilia Garlanda3, Soohyun Kim4, Suzhao Li4, Frank L van de Veerdonk5, Charles A Dinarello6, Luigina Romani1.
Abstract
Since IL-37 transgenic mice possesses broad anti-inflammatory properties, we assessed whether recombinant IL-37 affects inflammation in a murine model of invasive pulmonary aspergillosis. Recombinant human IL-37 was injected intraperitoneally into mice prior to infection and the effects on lung inflammation and inflammasome activation were evaluated. IL-37 markedly reduced NLRP3-dependent neutrophil recruitment and steady state mRNA levels of IL-1β production and mitigated lung inflammation and damage in a relevant clinical model, namely aspergillosis in mice with cystic fibrosis. The anti-inflammatory activity of IL-37 requires the IL-1 family decoy receptor TIR-8/SIGIRR. Thus, by preventing activation of the NLRP3 inflammasome and reducing IL-1β secretion, IL-37 functions as a broad spectrum inhibitor of the innate response to infection-mediated inflammation, and could be considered to be therapeutic in reducing the pulmonary damage due to non-resolving Aspergillus infection and disease.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25375146 PMCID: PMC4223056 DOI: 10.1371/journal.ppat.1004462
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Figure 1IL-37 reduces inflammatory cell recruitment in mice with inflammatory aspergillosis.
C57BL/6 mice were infected intranasally (in) with A. fumigatus and pretreated one time with different doses IL-37 administered intraperitoneally (ip) at different times before the infection. Mice were assessed for: (A) fungal growth (Log10 CFU, mean±SD) in the lungs at 1 and 3 days post-infection (dpi); (B) BAL fluid morphometry [number of total (T) cells and polymorphonuclear neutrophils (P) upon May Grunwald Giemsa staining. Values represent the mean±SD of three mice per group and are representative of 3 independent experiments]; (C) lung histology (periodic acid-Schiff and, in the inset, TUNEL staining). Red arrows indicate PMN and white arrows indicate increased deposition of DNA on lung parenchyma (in TUNEL-stained sections). Scale bars, 25 µm; (D) myeloperoxidase (Mpo), Cxcl1 and Cxcl2 mRNA expression by RT-PCR on total lung cells; (E) lung histology (periodic acid-Schiff staining, scale bars, 25 µm) and (F) Mpo, Cxcl1 and Cxcl2 mRNA expression (RT-PCR on total lung cells) in mice pretreated with IL-37 given ip or in, at different hours before the infection. (G) Numbers of CD11b/Gr1–positive cells were assessed by flow cytometry of total lung cells from LPS-treated mice. Data are representative (histology) or pooled from three experiments. *P<0.05,**P<0.01, treated vs untreated (None) mice. Naïve, uninfected and untreated mice.
Figure 2IL-37 impairs inflammasome activation in mice with aspergillosis.
C57BL/6 mice were infected intranasally with A. fumigatus and treated intraperitoneally with recombinant IL-37 precursor, at the indicated doses, 96, 48 and 1 hour before the infection. (A) NLRP3 expression in the lung by immunofluorescence staining with anti-CIAS1/Nlrp3 antibody. In the insets, positive staining of epithelial cells. Nuclei were counterstained with DAPI. Scale bars, 100 µm. (B, E) Gene expression on total lung cells by RT-PCR. (C) Cytokine production (ELISA) on lung homogenates. (D) Immunoblot analysis on whole lung lysates of IL-1β and Caspase 1 using rabbit specific antibodies and rabbit anti-actin. Goat anti-rabbit IgG-HRP were used as secondary antibody. Corresponding pixel density ratio was normalized against actin. Assays were done a day after the infection. Data are representative (immunoblotting) or pooled from three experiments. *P<0.05, **P<0.01, treated vs untreated (None) mice. Naïve, uninfected and untreated mice.
Figure 3NLRP3-deficient mice exhibit reduced neutrophil recruitment and IL-1β production in pulmonary aspergillosis.
C57BL/6 and Nlrp3 mice were infected intranasally with A. fumigatus and treated with 1000 ng/mouse recombinant IL-37 precursor administered intraperitoneally 1 hour before the infection. (A) BAL fluid morphometry [number of total (T) cells and polymorphonuclear neutrophils (P). Values represent the mean±SD of three mice per group and are representative of 3 independent experiments]. (B) Lung histology (periodic acid-Schiff staining) and cell recruitment (insets). Scale bars, 100 µm and 25 µm, respectively. Arrows indicate neutrophils. (C) Mpo and Cxcl2 mRNA expression by RT-PCR on total lung cells. (D) IL-1β production (ELISA on lung homogenates). Assays were done 3 days after the infection. Data are representative (histology) or pooled from three experiments. *P<0.05, Nlrp3 C57BL/6 mice and treated vs untreated (None) mice. Naïve, uninfected and untreated mice.
Figure 4IL-37 dampens inflammasome activation in phagocytic cells.
Alveolar macrophages and epithelial cells from naive mice and peripheral neutrophils were pre-exposed to recombinant IL-37 precursor for 8 hours before stimulation with live Aspergillus conidia for 2 hours. (A) Percent of phagocytosis and conidiocidal activity. (B) Il1b and Nos2 mRNA expression by RT-PCR on total lung cells. Ct, control cells. None, Aspergillus-pulsed, untreated cells. (C) Activation of distinct intracellular kinases in RAW cells, using Proteome Profiler Array, pre-exposed to 100 ng/ml IL-37 for 8 hours before stimulation with live Aspergillus conidia for 30 min. Data are representative (Proteome Profiler Array) or pooled from two experiments. *P<0.05,**P<0.01, ***P<0.001, IL-37-stimulated vs unstimulated cells.
Figure 5IL-37 fails to inhibit inflammasome activation in Tir8 mice.
Tir8 mice were infected intranasally with A. fumigatus and treated intraperitoneally with recombinant IL-37 precursor, at the dose of 1000 ng/mouse, 1 hour before the infection. (A) BAL fluid morphometry [number of total (T) cells and polymorphonuclear neutrophils (P). Values represent the mean±SD of three mice per group and are representative of 3 independent experiments]. (B) Lung histology (PAS-stained sections). Scale bars, 25 µm. In the insets, NLRP3 expression by immunofluorescence staining of epithelial cells. Images were acquired using a fluorescence microscope with a 40× objective. Nuclei were counterstained with DAPI. (C) Mpo and Cxcl2 mRNA expression and (D) cytokine gene expression (RT-PCR) on total lung cells. (E) Immunoblot with rabbit polyclonal IL-1β-specific antibody on whole lung lysates. Assays were done 3 days post-infection. Data are representative (histology) or pooled from two experiments. None, untreated mice. Naïve, uninfected and untreated mice.
Figure 6IL-37 restrains inflammation in fungal allergy and Cftr mice.
(A) Lung histology (PAS- and Masson's trichrome-stained sections, scale bars 100 and 25 (insets) µm); (B) hydroxyproline content (µg/lung); (C) expression of mucins (RT-PCR on total lung cells); (D) expression of cytokines and Th transcription factors in total lung cells from mice with ABPA and treated with IL-37. None, untreated mice. Naïve, uninfected and untreated mice. (E) Fungal growth (Log10 CFU, mean±SD) in the lungs of Cftr mice infected intranasally with A. fumigatus and treated intraperitoneally with IL-37, at the dose of 1000 ng/mouse, 1 hour before the infection. (F) BAL fluid morphometry [number of total (T) cells and polymorphonuclear neutrophils (P) upon May Grunwald Giemsa staining]. (G) Lung histology (periodic acid-Schiff staining) and cell recruitment (insets). Scale bars, 100 µm and 25 µm in the insets; (H) Mpo and Cxcl2 mRNA expression and (I) cytokine gene expression on total lung cells by RT-PCR, 3 days after the infection. Data are pooled from two experiments. *P<0.05, **P<0.01, treated vs untreated (None) mice. Naïve, uninfected and untreated mice.
Real-time murine PCR primers used in this study.
| Gene name | Primer sequence |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, | |
|
| Forward, |
| Reverse, |